Chemical Compound Review:
Exjade 4-[(3Z,5E)-3,5-bis(6-oxo-1- cyclohexa-2,4...
Synonyms:
Deferasirox, Deferasiroxum, PubChem20503, ICL-670, SureCN62042, ...
Kourakli-Symeonidis,
Neufeld,
Karimian,
Mueller,
Drelichman,
Kelly,
Bernaudin,
Forni,
Thuret,
Vichinsky,
Perrotta,
Files,
Olivieri,
Fung,
Onyekwere,
Lane,
Giardina,
Ashraf S. Ibrahim,
Teclegiorgis Gebermariam,
Yue Fu,
Lin Lin,
Mohamed I. Husseiny,
Samuel W. French,
Julie Schwartz,
Christopher D. Skory,
John E. Edwards,
Brad J. Spellberg,
Alberti,
Leung-Toung,
Nick,
Janka-Schaub,
Capra,
Fattoum,
Athanassiou-Metaxa,
Kattamis,
Cohen,
Galanello,
Alberti,
Kretz,
Ressayre-Djaffer,
Hassell,
Link,
Spino,
Wu,
Konijn,
Verissimo,
Piga,
Swerdlow,
Ressayre-Djaffer,
Vermylen,
Konijn,
Hershko,
Cappellini,
Gross,
Agaoglu,
Holland,
Forgiarini,
Coates,
Opitz,
Hershko,
Sergejew,
Tam,
Wang,
Breuer,
Eckman,
Camenisch,
Schnebli,
Aydinok,
Marks,
Porter,
Okpala,
Weiss,
Fresneau,
Kilinc,
Link,
Wilson,
Porter,
Marks,
Okpala,
Patel,
Fischer,
Bejaoui,
Cabantchik,
Magnano,
Cabantchik,
Li,
Hasinoff,
Coates,
- A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Cappellini, M.D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., Aydinok, Y., Kattamis, A., Kilinc, Y., Porter, J., Capra, M., Galanello, R., Fattoum, S., Drelichman, G., Magnano, C., Verissimo, M., Athanassiou-Metaxa, M., Giardina, P., Kourakli-Symeonidis, A., Janka-Schaub, G., Coates, T., Vermylen, C., Olivieri, N., Thuret, I., Opitz, H., Ressayre-Djaffer, C., Marks, P., Alberti, D. Blood (2006)
- Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Neufeld, E.J. Blood (2006)
- Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Reed, C., Ibrahim, A., Edwards, J.E., Walot, I., Spellberg, B. Antimicrob. Agents Chemother. (2006)
- The iron chelator deferasirox protects mice from mucormycosis through iron starvation. Ibrahim, A.S., Gebermariam, T., Fu, Y., Lin, L., Husseiny, M.I., French, S.W., Schwartz, J., Skory, C.D., Edwards, J.E., Spellberg, B.J. J. Clin. Invest. (2007)
- The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Hasinoff, B.B., Patel, D., Wu, X. Free Radic. Biol. Med. (2003)
- A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Vichinsky, E., Onyekwere, O., Porter, J., Swerdlow, P., Eckman, J., Lane, P., Files, B., Hassell, K., Kelly, P., Wilson, F., Bernaudin, F., Forni, G.L., Okpala, I., Ressayre-Djaffer, C., Alberti, D., Holland, J., Marks, P., Fung, E., Fischer, R., Mueller, B.U., Coates, T. Br. J. Haematol. (2007)
- Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Glickstein, H., El, R.B., Link, G., Breuer, W., Konijn, A.M., Hershko, C., Nick, H., Cabantchik, Z.I. Blood (2006)
- In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. Weiss, H.M., Fresneau, M., Camenisch, G.P., Kretz, O., Gross, G. Drug Metab. Dispos. (2006)
- Objectives and mechanism of iron chelation therapy. Hershko, C., Link, G., Konijn, A.M., Cabantchik, Z.I. Ann. N. Y. Acad. Sci. (2005)
- The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox. Chantrel-Groussard, K., Gaboriau, F., Pasdeloup, N., Havouis, R., Nick, H., Pierre, J.L., Brissot, P., Lescoat, G. Eur. J. Pharmacol. (2006)
- New therapies for sickle cell disease. Okpala, I.E. Hematol. Oncol. Clin. North Am. (2005)
- Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Shashaty, G., Frankewich, R., Chakraborti, T., Choudary, J., Al-Fayoumi, S., Kacuba, A., Castillo, S., Robie-Suh, K., Rieves, D., Weiss, K., Pazdur, R. Oncology (Williston Park, N.Y.) (2006)
- Chelator-induced iron excretion in iron-overloaded marmosets. Sergejew, T., Forgiarini, P., Schnebli, H.P. Br. J. Haematol. (2000)
- ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Hershko, C., Konijn, A.M., Nick, H.P., Breuer, W., Cabantchik, Z.I., Link, G. Blood (2001)
- Iron chelator research: past, present, and future. Tam, T.F., Leung-Toung, R., Li, W., Wang, Y., Karimian, K., Spino, M. Current medicinal chemistry. (2003)
- Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. Galanello, R., Piga, A., Alberti, D., Rouan, M.C., Bigler, H., Séchaud, R. Journal of clinical pharmacology. (2003)